Now or later? Switching therapies in metastatic breast cancer
Mené sur 315 patient(e)s atteint(e)s d'un cancer du sein HR+ de stade avancé, cet essai international de phase III évalue l'intérêt, du point de vue de la survie sans progression, de remplacer le traitement standard de première ligne par le camizestrant dès qu'une mutation ESR1 apparaît dans l'ADN tumoral circulant
In contemporary management of patients with hormone receptor-positive, HER2-negative metastatic breast cancer, it is standard to switch therapies at tumour progression, defined by RECIST criteria in clinical trials, and by other measures (many, ironically, considered non-measurable by RECIST) in clinical practice, including subtler radiological changes, findings on examination, rising tumour markers, or increased symptoms related to cancer.1 Accordingly, in the clinic, a treatment change can be considered for symptomatic progression despite radiologically stable disease, or the same treatment might be continued beyond asymptomatic oligoprogression.2 These approaches reflect the core goals of controlling tumour-related symptoms, preserving quality of life, and navigating a chronic disease where patients will pursue multiple therapeutic options.
The Lancet Oncology , commentaire, 2026